The unique CD30+OX40+ Treg subset that can be validated at single-cell resolution, in both Caucasian and Asian cohorts, in tissue and liquid biopsies, may be used as a potential immune-oncology biomarker to diagnose and prognosticate CRC. This evidence concerns the gene TNFRSF8 and colorectal carcinoma.